SouthernWorldwide.com – Constituents consistently express significant worries regarding the escalating cost of living, with healthcare expenses being a particularly acute concern.
A substantial portion of Americans, approximately one-third, report having to reduce spending in other areas to afford their healthcare. Numerous surveys consistently highlight that healthcare costs are a paramount economic worry for Americans, frequently ranking above other financial anxieties. In fact, earlier this year, around 75 percent of voters indicated that the affordability of healthcare would be a deciding factor in their upcoming election choices.
At a juncture when many households are grappling with rising prices, it is imperative for Congress to concentrate on initiatives that can yield tangible and immediate improvements. Lowering the cost of insulin stands out as one such critical area.
Unlike many other household expenditures, insulin is not a commodity that individuals can simply cut back on when financial resources are strained. Close to 8.4 million Americans depend on insulin to manage their diabetes. Alarmingly, up to one in five insulin users have admitted to rationing their medication due to its prohibitive cost, thereby jeopardizing their health. For individuals with Type 1 diabetes, insulin is not merely a medication but a literal lifeline.
Even families who possess health insurance are increasingly finding that premiums, deductibles, and out-of-pocket expenses are becoming unmanageably high.
In a nation as prosperous as the United States, no individual should be forced to make a choice between life-saving medication and meeting their essential financial obligations.
Fortunately, there is no need for speculation regarding effective strategies to make insulin affordable for the millions of Americans who rely on it for survival. The Inflation Reduction Act successfully implemented a cap on monthly insulin costs for Medicare beneficiaries, thereby shielding seniors from the exorbitant price of a medication they require daily.
The impact of this legislation is evident. A recent analysis by Johns Hopkins revealed a significant increase in the proportion of Medicare patients paying $35 or less for a month’s supply of insulin, rising from 48% in 2019 to 75% in 2023. Concurrently, average out-of-pocket expenses saw a reduction of more than half.
Furthermore, the Medicare insulin cap has not only addressed monthly costs but has also led to a decrease in emergency department visits and hospitalizations among seniors experiencing complications related to diabetes.
However, Congress has yet to extend these crucial protections to individuals outside of the Medicare program. Millions of Americans with private insurance remain without similar safeguards against the high cost of insulin.
Earlier this year, a distressing incident occurred where a couple in Mississippi had to pay $194 for a single month’s supply of insulin for their two-year-old son. The ability for a family to afford essential medication like insulin should not be contingent upon the type of insurance they possess.
This issue is deeply personal for me. My granddaughter, Elle, was diagnosed with Type 1 diabetes shortly after her eighth birthday. Like countless other families, ours understands the constant vigilance and meticulous monitoring required to manage this chronic condition.
This challenging reality does not have to persist. The demonstrable success of the Medicare insulin cap provides a clear and actionable path forward. It is for this reason that I, along with Senators Susan Collins, Raphael Warnock, and John Kennedy, have introduced the bipartisan INSULIN Act. This legislation aims to cap monthly insulin costs at $35 for individuals with employer-sponsored insurance and also provides assistance for uninsured patients to access affordable insulin.
Ensuring that Americans can afford the medications they need should not be a matter of partisan division. The INSULIN Act enjoys broad support, with backing from 13 Republicans and 13 Democrats, including senators with diverse ideological stances such as Tammy Baldwin and Tommy Tuberville.
Given the clear calls from our constituents for financial relief, this bipartisan proposal represents a significant and immediate step that Congress can take to substantively address their pressing concerns.
Support for reducing insulin costs extends far beyond the halls of Congress. Individuals from all political affiliations – Democrats, Republicans, and Independents – overwhelmingly endorse capping insulin costs. Few issues garner such a widespread consensus.
We have already demonstrated that achieving lower insulin costs is a feasible objective. It is unacceptable for families to bear higher costs for the same essential medication simply because they are not Medicare beneficiaries. It is time to complete this vital task.
